CBD DEA Epilepsy THC 
The Blunt Truth
OCTOBER 15, 2019
We have noted previously that the federal Drug Enforcement Agency (DEA) recently announced that drugs that include CBD (cannabidiol) with less than 0.1% of THC (tetrahydrocannabinols) are now considered Schedule V drugs provided they are approved by the federal Food and Drug Administration (FDA). Medical Marijuana, Inc.,
Freedom Leaf
OCTOBER 15, 2018
Though it doesn’t get users high like THC-dominant products, CBD is all the rage these days due to its medical benefits and gray-area legality. All other CBD formulations remain in Schedule I, which is for drugs with a “high potential for abuse” and “no currently accepted medical use.” will top $1.9 billion by 2022.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 20, 2019
Specifically, airmen are concerned about the safety of cannabidiol (CBD) oil use and how such use impacts an airman’s medical certificate. The compound responsible for the euphoric, mind-altering effect is tetrahydrocannabinol (THC). One such compound being widely marketed is CBD oil. Product labels are often inaccurate.
CannaMD
AUGUST 8, 2020
In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. So sit back, relax – and if you can’t relax, grab some CBD! What is CBD? Let’s clear up one of the biggest sources of confusion right off the bat: CBD is a cannabis compound called cannabidiol.
Cannabis Law Report
OCTOBER 15, 2019
We have noted previously that the federal Drug Enforcement Agency (DEA) recently announced that drugs that include CBD (cannabidiol) with less than 0.1% of THC (tetrahydrocannabinols) are now considered Schedule V drugs provided they are approved by the federal Food and Drug Administration (FDA). In Horn v.
MedicalJane
JUNE 29, 2018
The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Prior to this week, the U.S.
Veriheal
APRIL 11, 2022
Drug Enforcement Agency (DEA). According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. CBD is also contained in another FDA-approved medicine called Epidiolex®.
Expert insights. Personalized for you.
87 
Let's personalize your content